Literature DB >> 28867556

Neoantigen Vaccines Pass the Immunogenicity Test.

Gerald P Linette1, Beatriz M Carreno2.   

Abstract

Neoantigens arising from tumor-specific genomic alterations constitute authentic non-self antigens and represent a new class of targets for cancer immunotherapy. Recent reports on various vaccine platforms targeting neoantigens suggest a basis for precision therapies customized to each patient's tumor mutational profile.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28867556      PMCID： PMC5624828          DOI： 10.1016/j.molmed.2017.08.007

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN： 1471-4914            Impact factor:   11.951


  8 in total

1.  Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells.

Authors:  Beatriz M Carreno; Vincent Magrini; Michelle Becker-Hapak; Saghar Kaabinejadian; Jasreet Hundal; Allegra A Petti; Amy Ly; Wen-Rong Lie; William H Hildebrand; Elaine R Mardis; Gerald P Linette
Journal:  Science       Date:  2015-04-02       Impact factor: 47.728

2.  Mutant MHC class II epitopes drive therapeutic immune responses to cancer.

Authors:  Sebastian Kreiter; Mathias Vormehr; Niels van de Roemer; Mustafa Diken; Martin Löwer; Jan Diekmann; Sebastian Boegel; Barbara Schrörs; Fulvia Vascotto; John C Castle; Arbel D Tadmor; Stephen P Schoenberger; Christoph Huber; Özlem Türeci; Ugur Sahin
Journal:  Nature       Date:  2015-04-22       Impact factor: 49.962

Review 3.  Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy.

Authors:  Pierre G Coulie; Benoît J Van den Eynde; Pierre van der Bruggen; Thierry Boon
Journal:  Nat Rev Cancer       Date:  2014-02       Impact factor: 60.716

Review 4.  Vaccines targeting helper T cells for cancer immunotherapy.

Authors:  Marit Melssen; Craig L Slingluff
Journal:  Curr Opin Immunol       Date:  2017-07-26       Impact factor: 7.486

5.  The Cancer Genome Atlas Pan-Cancer analysis project.

Authors:  John N Weinstein; Eric A Collisson; Gordon B Mills; Kenna R Mills Shaw; Brad A Ozenberger; Kyle Ellrott; Ilya Shmulevich; Chris Sander; Joshua M Stuart
Journal:  Nat Genet       Date:  2013-10       Impact factor: 38.330

Review 6.  The Basis of Oncoimmunology.

Authors:  A Karolina Palucka; Lisa M Coussens
Journal:  Cell       Date:  2016-03-10       Impact factor: 41.582

7.  An immunogenic personal neoantigen vaccine for patients with melanoma.

Authors:  Patrick A Ott; Zhuting Hu; Derin B Keskin; Sachet A Shukla; Jing Sun; David J Bozym; Wandi Zhang; Adrienne Luoma; Anita Giobbie-Hurder; Lauren Peter; Christina Chen; Oriol Olive; Todd A Carter; Shuqiang Li; David J Lieb; Thomas Eisenhaure; Evisa Gjini; Jonathan Stevens; William J Lane; Indu Javeri; Kaliappanadar Nellaiappan; Andres M Salazar; Heather Daley; Michael Seaman; Elizabeth I Buchbinder; Charles H Yoon; Maegan Harden; Niall Lennon; Stacey Gabriel; Scott J Rodig; Dan H Barouch; Jon C Aster; Gad Getz; Kai Wucherpfennig; Donna Neuberg; Jerome Ritz; Eric S Lander; Edward F Fritsch; Nir Hacohen; Catherine J Wu
Journal:  Nature       Date:  2017-07-05       Impact factor: 49.962

8.  Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.

Authors:  Ugur Sahin; Evelyna Derhovanessian; Matthias Miller; Björn-Philipp Kloke; Petra Simon; Martin Löwer; Valesca Bukur; Arbel D Tadmor; Ulrich Luxemburger; Barbara Schrörs; Tana Omokoko; Mathias Vormehr; Christian Albrecht; Anna Paruzynski; Andreas N Kuhn; Janina Buck; Sandra Heesch; Katharina H Schreeb; Felicitas Müller; Inga Ortseifer; Isabel Vogler; Eva Godehardt; Sebastian Attig; Richard Rae; Andrea Breitkreuz; Claudia Tolliver; Martin Suchan; Goran Martic; Alexander Hohberger; Patrick Sorn; Jan Diekmann; Janko Ciesla; Olga Waksmann; Alexandra-Kemmer Brück; Meike Witt; Martina Zillgen; Andree Rothermel; Barbara Kasemann; David Langer; Stefanie Bolte; Mustafa Diken; Sebastian Kreiter; Romina Nemecek; Christoffer Gebhardt; Stephan Grabbe; Christoph Höller; Jochen Utikal; Christoph Huber; Carmen Loquai; Özlem Türeci
Journal:  Nature       Date:  2017-07-05       Impact factor: 49.962
  8 in total
  15 in total

1.  Automated generation of immature dendritic cells in a single-use system.

Authors:  Andrew Kozbial; Lekhana Bhandary; Bradley B Collier; Christopher S Eickhoff; Daniel F Hoft; Shashi K Murthy
Journal:  J Immunol Methods       Date:  2018-04-03       Impact factor: 2.303

Review 2.  Tumor-Infiltrating Lymphocytes in the Checkpoint Inhibitor Era.

Authors:  Gerald P Linette; Beatriz M Carreno
Journal:  Curr Hematol Malig Rep       Date:  2019-08       Impact factor: 3.952

3.  Bayesian multiple instance regression for modeling immunogenic neoantigens.

Authors:  Seongoh Park; Xinlei Wang; Johan Lim; Guanghua Xiao; Tianshi Lu; Tao Wang
Journal:  Stat Methods Med Res       Date:  2020-05-13       Impact factor: 3.021

4.  Tumor cells endowed with professional antigen-presenting cell functions prime PBLs to generate antitumor CTLs.

Authors:  Chiara Chiozzini; Eleonora Olivetta; Massimo Sanchez; Claudia Arenaccio; Flavia Ferrantelli; Patrizia Leone; Maurizio Federico
Journal:  J Mol Med (Berl)       Date:  2019-06-03       Impact factor: 4.599

5.  Deep learning-based prediction of the T cell receptor-antigen binding specificity.

Authors:  Tianshi Lu; Ze Zhang; James Zhu; Yunguan Wang; Peixin Jiang; Xue Xiao; Chantale Bernatchez; John V Heymach; Don L Gibbons; Jun Wang; Lin Xu; Alexandre Reuben; Tao Wang
Journal:  Nat Mach Intell       Date:  2021-09-23

6.  pVACtools: A Computational Toolkit to Identify and Visualize Cancer Neoantigens.

Authors:  Jasreet Hundal; Susanna Kiwala; Joshua McMichael; Christopher A Miller; Huiming Xia; Alexander T Wollam; Connor J Liu; Sidi Zhao; Yang-Yang Feng; Aaron P Graubert; Amber Z Wollam; Jonas Neichin; Megan Neveau; Jason Walker; William E Gillanders; Elaine R Mardis; Obi L Griffith; Malachi Griffith
Journal:  Cancer Immunol Res       Date:  2020-01-06       Impact factor: 11.151

Review 7.  Neoantigen Vaccine Delivery for Personalized Anticancer Immunotherapy.

Authors:  Yugang Guo; Kewen Lei; Li Tang
Journal:  Front Immunol       Date:  2018-07-02       Impact factor: 7.561

Review 8.  Neoantigen-Specific Adoptive Cell Therapies for Cancer: Making T-Cell Products More Personal.

Authors:  Valentina Bianchi; Alexandre Harari; George Coukos
Journal:  Front Immunol       Date:  2020-06-26       Impact factor: 7.561

Review 9.  The Interplay Between the Genetic and Immune Landscapes of AML: Mechanisms and Implications for Risk Stratification and Therapy.

Authors:  Lourdes M Mendez; Ryan R Posey; Pier Paolo Pandolfi
Journal:  Front Oncol       Date:  2019-11-07       Impact factor: 6.244

Review 10.  Computational Prediction and Validation of Tumor-Associated Neoantigens.

Authors:  Vladimir Roudko; Benjamin Greenbaum; Nina Bhardwaj
Journal:  Front Immunol       Date:  2020-01-24       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.